TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration.
Eye (London, England)
View this publicationEye (London, England)
View this publicationScientific reports
View this publicationDiagnostics (Basel, Switzerland)
View this publicationMolecular cancer
View this publicationNeurology(R) neuroimmunology & neuroinflammation
View this publicationFrontiers in immunology
View this publicationCardiovascular research
View this publicationNature communications
View this publicationScientific reports
View this publicationCell reports
View this publication